Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuromuscular
At what point do you consider weaning steroids or immuno-modulating agents in patients with Myasthenia Gravis?
How long do you monitor for clinical stability?
Related Questions
Do you find IVIG to be an effective maintenance therapy for myasthenia gravis?
How do you treat fatigue symptoms in myasthenia gravis?
Do you always biopsy patients who present with classic skin findings of dermatomyositis?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
Do you perform EMG and repetitive nerve stimulation in patients with ocular myasthenia gravis, particularly those who are AChR-positive, to assess for electrophysiological evidence of generalized disease?
How do you identify patients with false positive AcHR antibodies?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
Would you add immunosuppression in ocular myasthenia gravis patients who are symptomatically well-controlled on pyridostigmine?
How do you counsel patients who wish to travel to high altitudes with myasthenia gravis?
When do you obtain nerve biopsy to evaluate for vasculitic neuropathy in patients with distal symmetric polyneuropathies?